New first-line treatment option for metastatic prostate cancer
https://www.facingourrisk.org/XRAY/first-line-treatment-for-metastatic-prostate-cancer
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate
The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Should I have genetic testing for a mutation in genes linked to prostate cancer?
- Should I have tumor testing?
- Is Talzenna or another PARP inhibitor an option for me?
- Will my health insurance pay for Talzenna?
Open Clinical Trials
The following studies are looking at PARP inhibitors and similar agents for treating people with advanced prostate cancer.
- NCT05932862: Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors. The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors, including breast cancer.
- NCT05005728: XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. This study will look at the safety and clinical activity of the drug XmAb20717 alone or in combination with standard-of-care anticancer therapies in patients with metastatic castration-resistant prostate cancer who have been treated with at least 2 prior lines of treatment.
- NCT03317392: Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis. This study is measuring the best dosage for and side effects of the drug combination olaparib and radium-223 to treat men with mCRPC that has spread to the bones.
- NCT05417594: Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study). This study is looking at a new PARP inhibitor called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed.
Other clinical trials for people with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.